Two cases of telbivudine-induced myopathy in siblings with chronic hepatitis B

Eun Hye Kim, Hana Park, Kun Ho Lee, Sang Hoon Ahn, Seung-Min Kim, and Kwang-Hyub Han

INTRODUCTION

Chronic hepatitis B (CHB) is a major health problem worldwide. It is estimated that approximately 400 million people are infected with hepatitis B virus (HBV) globally. CHB can progress to cirrhosis, decompensated cirrhosis, hepatocellular carcinoma (HCC), and death. Korea is an HBV endemic area; therefore, CHB is a major public health problem in Korea. Several nucleos(t)ide analogues (NAs) have been developed over the past decade, and administration of NAs has played a crucial role in the treatment of CHB. In addition to lamivudine, there are currently four oral NAs available for CHB treatment, including adefovir dipivoxil, entecavir, telbivudine, and tenofovir, which have shown greater antiviral activity compared with a placebo or lamivudine in patients with CHB.

Telbivudine (β-L-2′-deoxythymidine) is a new synthetic nucleoside analogue and is a bioavailable L-nucleoside with specific ant-HBV activity in vitro. Since telbivudine came on the market in October 2006, a new option has been given to clinicians to treat CHB patients, especially based on the results of the GLOBE trial. The GLOBE trial showed that telbivudine has more potent antiviral activity and less viral resistance compared with lamivudine. In the preclinical toxicological tests, telbivudine had no mutagenic or carcinogenic effects. A minority of telbivudine-treated patients experienced creatine kinase (CK) elevation, usually transient, and myopathy occurred rarely. However, in our recent clinical practice, we experienced myopathy with serum CK level elevation, which seemed to be associated with telbivudine in two patients who were siblings. Myopathy is characterized by muscle pain, weakness and moderately elevated CK levels. We report here the two cases of telbivudine-induced myopathy in patients with CHB to consider the adverse reaction mechanisms of telbivudine.
CASE REPORT

Case 1

A 28-year-old man who received telbivudine therapy for chronic hepatitis B presented with progressive weakness of both lower legs and difficulty in ascending stairs over the past 4 months. And also, he was unable to lift up a dumbbell and do pushups due to weakness in both arm. He was diagnosed with CHB 3 years ago and started taking 600 mg of telbivudine once daily for 9 months to control HBV activation. Since taking telbivudine, the serum viral DNA level gradually decreased from 100,000 IU/mL to 222 IU/mL, and the serum alanine aminotransferase (ALT) and aspartate aminotransferase (AST) levels were also normalized. However, he showed muscle weakness since taking telbivudine. Although there was no symptoms such as dysphagia, cramps, or sensory abnormality, the patient suffered from progressive and generalized weakness, especially of his legs, and had difficulty climbing stairs. He exhibited motor weakness (grade 4) of the hip flexor, making it difficult for him to stand up from the sitting position, but there was no sign of abnormal deep tendon reflex, muscle atrophy, or hypertrophy on physical examination. He had not taken any other medications that would be regarded as a cause of his symptoms while taking telbivudine. Laboratory examinations showed AST of 59 IU/L, ALT of 26 IU/L, total bilirubin of 0.9 mg/dL, blood urea nitrogen (BUN) of 15.4 mg/dL, and serum creatinine of 0.7 mg/dL. His serum CK level was elevated up to 788 IU/L (44-245 IU/L). Electromyography (EMG) was performed and showed a few positive sharp waves with polyphasic myopathic motor unit action potentials in the right vastus medialis, tibialis anterior, and biceps brachii muscles, which is consistent with the active stage of generalized myopathy (Fig. 1). We planned to perform a muscle biopsy for confirmation, but he refused to have a muscle biopsy. The serum CK level was elevated up to 728 IU/L, 4 months prior to this visit. At that time, he felt general weakness, but he did not stop taking telbivudine. Because most of telbivudine-related CK elevations were transient and increased CK levels decreased to normal range without any interruption. However, his symptoms persisted and CK elevation was also shown. Thus, he was diagnosed him with telbivudine-induced myopathy based on the clinical clues and EMG findings and decided to change the anti-viral agent to 0.5 mg entecavir once daily. He revisited our clinic at one month after telbivudine withdrawal, and his clinical symptoms subsequently improved to the extent that he was able to climb stairs easily. The serum CK level was also decreased to 326 IU/L.

Case 2

A 25-year-old man who received telbivudine therapy for chronic hepatitis B presented with progressive generalized weakness and difficulty exercising. He was diagnosed with CHB 4 years ago, and took lamivudine at first, but he changed to combination therapy of 600 mg of telbivudine once daily for 13 months and 10 mg of adefovir once to control HBV activation and lamivudine resistance. At 12 months after starting treatment, the HBV DNA level decreased to the undetectable range, and the elevated serum AST and ALT levels also decreased along with viral stabilization. However, the patient began to suffer from generalized weakness and difficult exercising since about 2 years after the treatment. He did not have dysphagia, cramps, or sensory symptoms and did not exhibit motor weakness. Laboratory analyses showed AST of 54 IU/L, ALT of 57 IU/L, total bilirubin of 0.4 mg/dL, BUN of 13.4 mg/dL, and serum creatinine of 1.15 mg/dL, and serum CK was elevated up to 2,992 IU/L. In this case, we did not conduct EMG. These two patients were siblings and they started taking telbivudine at the same time. Also, his symptoms were similar to those of his brother. His brother was diagnosed telbivudine-induced myopathy in advance. He visited the department of neurology and was...
were affected most frequently. The most common adverse reaction and the limb skeletal muscles of telbivudine. Myalgia accompanied by general weakness, was the most common treatment-related adverse effects were elevated CK levels was observed in 88 (12.9%) of 680 patients on the telbivudine arm. Myopathy, characterized by muscle pain, weakness, and elevated CK levels, was reported in two patients, which resolved after telbivudine was discontinued. Preliminary data in the GLOBE trial found that 9 (1.4%) patients had new onset of grade 3 or 4 CK elevations and 9 (1.4%) had myalgia or myositis between 104 and 156 weeks.

Since telbivudine was approved for the treatment of CHB, there have been a few studies reporting telbivudine-related adverse reactions. In the GLOBE trial, grade 3 or 4 elevation in CK levels was observed in 88 (12.9%) of 680 patients on the telbivudine arm. Myopathy, characterized by muscle pain, weakness, and elevated CK levels, was reported in two patients, which resolved after telbivudine was discontinued. Preliminary data in the GLOBE trial found that 9 (1.4%) patients had new onset of grade 3 or 4 CK elevations and 9 (1.4%) had myalgia or myositis between 104 and 156 weeks. The safety profile of telbivudine over three years was similar to that reported at two years in the GLOBE trial; most adverse effects were mild and transient in nature and no new safety signals were observed. The most common treatment-related adverse effects were elevated CK levels (7.5%), headache (3.6%), fatigue (2.9%), nausea (2.9%), diarrhea (2.2%), and nasopharyngitis (1.9%). Myalgia, myositis and muscular weakness were reported in 22 (5.3%), 2 (0.5%) and 2 (0.5%) patients, respectively. Xue-song Zhang et al. retrospectively reviewed five patients, and reported adverse reactions of the cardiac and nervous systems persisted for a long time after discontinuation of telbivudine, myalgia resolved in a short period of time. Although several authors have reported regarding telbivudine-related adverse reactions from Western and Eastern countries, there have been no reports in Korea, especially regarding telbivudine-related adverse reactions, such as CK elevation or myopathy. To the best of our knowledge, this is the first report in Korea regarding telbivudine-related myopathy.

In these cases, the interesting point was that the two patients were siblings. The two sibling patients had started treatment for CHB around the same time and had been taking telbivudine for 9 months and 13 months, respectively. The duration of telbivudine treatment was too short compared to the other reports. This is the reason that there may be a genetic problem to telbivudine-induced myopathy. When they had myalgia symptoms, both of their CK levels were elevated to 788 IU/L and 2,992 IU/L. According to the data from our institute, 20 (7.7%) of 259 patients who have been prescribed with telbivudine showed evidence of serum CK elevation during their follow-up periods. However, in most of them, serum CK elevation did not accompany with symptoms such as muscle weakness and myopathy. Furthermore, their increased CK levels decreased to the normal range without any interruption. Although we were not able to make clear the process of telbivudine-induced myopathy because the patients did not want to have a muscle biopsy and DNA study, their elevated CK levels decreased only after telbivudine withdrawal. In addition, their symptoms were also improved after discontinuing telbivudine treatment. Therefore, we were able to conclude that myopathy in these two patients might be related to telbivudine.

In Korea, CK elevation and myopathy were reported in many cases of long-term clevudine use. Some investigators have reported that these adverse reactions are related to mitochondrial toxicity because most NAs including telbivudine as well as clevudine commonly induce mitochondrial damage by inhibiting mitochondrial DNA polymerase. Another study has suggested that the mechanism is associated with cell energy metabolism. Mitochondria are involved in the production of energy. They contain many important proteins, enzymes, and carriers that participate in energy transduction. Deficiency in any of these leads to a poor substrate supply for oxidative phosphorylation and eventually to inadequate manufacture of the energy molecule ATP, which in turn causes mitochondrial disease. As a competitive substrate of natural thymidine, telbivudine is phosphorylated by host mitochondrial thymidine kinases to telbivudine-5’-triphosphate and thymidine kinases are extensively exhausted. As a result, the normal energy transduction process is disturbed. Moreover, in the process of phosphorylation, high levels of phosphates are cap-

DISCUSSION

Telbivudine, a new synthetic analogue of thymidine, is phosphorylated by host cellular kinases to telbivudine-5’-triphosphate, which has a half-life of 14 hours in vivo. Telbivudine-5’-triphosphate is then incorporated into HBV DNA by HBV polymerase, competing with thymidine-5’-triphosphate, the natural substrate. Once inserted, telbivudine-5’-triphosphate causes DNA chain termination, thereby inhibiting HBV replication.

Although several authors have reported regarding telbivudine-related adverse reactions from Western and Eastern countries, there have been no reports in Korea, especially regarding telbivudine-related adverse reactions, such as CK elevation or myopathy. To the best of our knowledge, this is the first report in Korea regarding telbivudine-related myopathy.

In these cases, the interesting point was that the two patients were siblings. The two sibling patients had started treatment for CHB around the same time and had been taking telbivudine for 9 months and 13 months, respectively. The duration of telbivudine treatment was too short compared to the other reports. This is the reason that there may be a genetic problem to telbivudine-induced myopathy. When they had myalgia symptoms, both of their CK levels were elevated to 788 IU/L and 2,992 IU/L. According to the data from our institute, 20 (7.7%) of 259 patients who have been prescribed with telbivudine showed evidence of serum CK elevation during their follow-up periods. However, in most of them, serum CK elevation did not accompany with symptoms such as muscle weakness and myopathy. Furthermore, their increased CK levels decreased to the normal range without any interruption. Although we were not able to make clear the process of telbivudine-induced myopathy because the patients did not want to have a muscle biopsy and DNA study, their elevated CK levels decreased only after telbivudine withdrawal. In addition, their symptoms were also improved after discontinuing telbivudine treatment. Therefore, we were able to conclude that myopathy in these two patients might be related to telbivudine.

In Korea, CK elevation and myopathy were reported in many cases of long-term clevudine use. Some investigators have reported that these adverse reactions are related to mitochondrial toxicity because most NAs including telbivudine as well as clevudine commonly induce mitochondrial damage by inhibiting mitochondrial DNA polymerase. Another study has suggested that the mechanism is associated with cell energy metabolism. Mitochondria are involved in the production of energy. They contain many important proteins, enzymes, and carriers that participate in energy transduction. Deficiency in any of these leads to a poor substrate supply for oxidative phosphorylation and eventually to inadequate manufacture of the energy molecule ATP, which in turn causes mitochondrial disease. As a competitive substrate of natural thymidine, telbivudine is phosphorylated by host mitochondrial thymidine kinases to telbivudine-5’-triphosphate and thymidine kinases are extensively exhausted. As a result, the normal energy transduction process is disturbed. Moreover, in the process of phosphorylation, high levels of phosphates are cap-

http://dx.doi.org/10.3350/cmh.2013.19.1.82 http://www.e-cmh.org
tured, which leads directly to exhaustion of ATP, resulting in poor energy supply. Nevertheless, at present, the biological mechanism of telbivudine-related CK elevations and myopathy is not yet clear. In this report, it was highly suspected that there might be a genetic problem related to this cell energy metabolism because the two patients were siblings. Further investigation for the genetic polymorphism associated with drug clearance in these two patients would be helpful to figure out the pharmaco-dynamic relevance.

In conclusion, here we report two uncommon cases of telbivudine-induced serum CK elevation accompanied with myopathy in CHB patients. Even though there have been no cases of telbivudine-induced myopathy in Korea, physicians should take into consideration the possibility of the relationship with telbivudine as in the cases of clevidine if they were met with such an adverse reaction in their clinical practice. In addition, further closer monitoring is recommended for the evaluation of CK elevation or myopathy in patients who were treated with telbivudine.

Conflicts of Interest

The authors have no conflicts to disclose.

REFERENCES

1. Lai CL, Yuen MF. Chronic hepatitis B--new goals, new treatment. N Engl J Med 2008;359:2488-2491.
2. Kim SS, Cheong JY, Cho SW. Current nucleos(t)ide analogue therapy for chronic hepatitis B. Gut Liver 2011;5:278-287.
3. Chang TT, Gish RG, de Man R, Gadano A, Sollano J, Chao YC, et al. A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B. N Engl J Med 2006;354:1001-1010.
4. Hadziyannis SJ, Tassopoulos NC, Heathcote EJ, Chang TT, Kitis G, Rizzetto M, et al. Adefovir dipivoxil for the treatment of hepatitis B e antigen-negative chronic hepatitis B. N Engl J Med 2003;348:800-807.
5. Jeong Id, Park NH, Kim BC, Park JH, Seo KW, Kim DH, et al. Efficacy of lamivudine in patients with hepatitis B e antigen-negative chronic liver diseases. Taehan Kan Hakhoe Chi 2003;9:69-78.
6. Lai CL, Chien RN, Leung NW, Chang TT, Guan R, Tai DI, et al. A one-year trial of lamivudine for chronic hepatitis B. Asia Hepatitis Lamivudine Study Group. N Engl J Med 1998;339:61-68.
7. Lai CL, Shouval D, Lok AS, Chang TT, Cheinquer H, Goodman Z, et al. Entecavir versus lamivudine for patients with HBeAg-negative chronic hepatitis B. N Engl J Med 2006;354:1011-1020.
8. Marcellin P, Chang TT, Lim SG, Tong MJ, Sievert W, Shiffman ML, et al. Adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B. N Engl J Med 2003;348:808-816.
9. Zhao S, Tang L, Fan X, Chen L, Zhou R, Dai X. Comparison of the efficacy of lamivudine and telbivudine in the treatment of chronic hepatitis B: a systematic review. Virol J 2010;7:211.
10. Buti MA. Telbivudine in the treatment of the chronic B hepatitis. Gastroenterol Hepatol 2008;31:258-263.
11. Liaw YF, Gane E, Leung N, Zeuzem S, Wang Y, Lai CL, et al. 2-Year GLOBE trial results: telbivudine is superior to lamivudine in patients with chronic hepatitis B. Gastroenterology 2009;136:486-495.
12. But DY, Yuen MF, Fung J, Lai CL. Safety evaluation of telbivudine. Expert Opin Drug Saf 2010;9:821-829.
13. Fleischer RD, Lok AS. Myopathy and neuropathy associated with nucleos(t)ide analog therapy for hepatitis B. J Hepatol 2009;51:787-791.
14. Matthews SJ. Telbivudine for the management of chronic hepatitis B virus infection. Clin Ther 2007;29:2635-2653.
15. McKeage K, Keam SJ. Telbivudine: a review of its use in compensated chronic hepatitis B. Drugs 2010;70:1857-1883.
16. Yurdaydin C, Akarca US. Treatment of chronic hepatitis B with telbivudine: wise hepatologists needed in hepatitis B endemic countries where treatment options are limited. Liver Int 2011;31:589-591.
17. Telbivudine: rhabdomyolysis and neuropathy. Prescrire Int 2010;19:171.
18. Zhang XS, Jin R, Zhang SB, Tao ML. Clinical features of adverse reactions associated with telbivudine. World J Gastroenterol 2008;14:3549-3553.
19. Finsterer J, Ay L. Myotoxicity of telbivudine in pre-existing muscle damage. Virol J 2010;7:323.
20. Gane EJ, Wang Y, Liaw YF, Hou J, Thongsawat S, Wan M, et al. Efficacy and safety of prolonged 3-year telbivudine treatment in patients with chronic hepatitis B. Liver Int 2011;31:676-684.
21. Kim HI, Park DI, Park JH, Cho YK, Sohn CI, Jeon WK, et al. Comparison between clevidine and entecavir treatment for antiviral-naive patients with chronic hepatitis B. Liver Int 2010;30:834-840.
22. Lee JA, Hwang HS, Yoo DH, Paik SS, Jang SJ, Kim YH, et al. 18F-FDG PET/CT of drug-induced myopathy in a patient with chronic hepatitis B on long-term clevidine therapy. Eur J Nucl Med Mol Imaging 2011;38:790-791.
23. Shin SR, Yoo BC, Choi MS, Lee DH, Song SM, Lee JH, et al. A comparison of 48-week treatment efficacy between clevidine and entecavir in treatment-naïve patients with chronic hepatitis B. Hepatol Int 2011;5:664-670.
24. Tak WY, Park SY, Cho CM, Jung MK, Jeon SW, Kweon YO, et al. Clinical, biochemical, and pathological characteristics of clevidine-associated myopathy. J Hepatol 2010;52:261-266.
25. Yang CY, Park SA, Kim HS, Shin Yi. Polymyositis in patients taking antiviral clevidine therapy: a report of two cases. NeuroRehabilita-
26. Bishop JB, Tani Y, Witt K, Johnson JA, Peddada S, Dunnick J, et al. Mitochondrial damage revealed by morphometric and semiquan-
titative analysis of mouse pup cardiomyocytes following in utero and postnatal exposure to zidovudine and lamivudine. Toxicol Sci 2004;81:512-517.